Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 17;220(7):e20221649. doi: 10.1084/jem.20221649

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 5. — Deletion of Ptpn6 (Shp1) alleviates the signaling defect in GRB2-deficient thymocytes. CD3+CD4 antibody activation of +/+, CD2-iCre;Grb2^f/f, CD2-iCre;Ptpn6^f/f, and CD2-iCre;Grb2^f/f;Ptpn6^f/f thymocytes. Thymocytes were rested for 6 h at 37°C, pre-incubated with biotinylated anti-CD3 and anti-CD4 antibodies, then streptavidin was added for the indicated times at 37°C. Cells were lysed at 4°C and proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, then blotted with the indicated antibodies. Results shown are representative of three independent experiments. Source data are available for this figure: SourceData F5.